All In Biotech

Drug Trial Radar · NCT04292119

Lorlatinib Combinations in Lung Cancer

A Phase IB/II Study of Lorlatinib Combinations in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

Last checked: Nov 19, 2026Latest source record: Mar 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

96

Planned (sponsor's estimate)

Start

May 1, 2020

Primary completion

Dec 1, 2022

Study completion Mar 1, 2023

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Array BioPharma; Pfizer
First posted
Mar 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. * This research study involves four study drugs. * Lorlatinib * Binimetinib * Crizotinib * TNO155

Conditions

  • Lung Cancer
  • Anaplastic Lymphoma Kinase Gene Translocation
  • ROS1 Rearrangement
  • Relapsed Cancer
  • MET Amplification
  • Resistant Cancer
  • NSCLC

Interventions

  • LorlatinibDrug

    Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155. Crizotinib taken orally twice daily for 28 days.

  • CrizotinibDrug

    Crizotinib will be taken orally twice daily for 28 days. Binimetnib taken orally twice daily for 28 days.

  • BinimetinibDrug

    Binimetinib will be taken orally twice daily for 28 days.

  • TNO155Drug

    TNO155 will be taken orally once daily for 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose as assessed by CTCAE v5.0. Phase I.Time frame: 28 days (binimetinib and crizotinib arm), 21 days (TNO155 arm)
  2. The objective response rate, including partial and complete responses, as evaluated by RECIST v1.1. Phase IITime frame: 24 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.